AstraZenecaの空売り状況は、投資家がAstraZenecaの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

AstraZeneca (NASDAQ:AZN) 株価情報, 空売り情報

AstraZeneca

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.

AstraZeneca PLC - American Depositary Shares

AstraZeneca PLC

Precidian ETFs Trust AstraZeneca PLC ADRhedged

AZN Capital Corp

Biotech

Large Cap

News

Health Care

General

AstraZeneca's High-Level Results From POTOMAC Phase 3 Trial Showed One Year Of Treatment With Imfinzi (Durvalumab) Plus Standard-of-care Bacillus Calmette-guérin (BCG) Induction And Maintenance Therapy Demonstrated Improvement In Disease-Free Survival For Patients With High-Risk Non-Muscle-Invasive Bladder Cancer Compared To BCG Induction And Maintenance Therapy Alone

As the drug industry is in the middle of a growing policy maelstrom in Washington, D.C., investors are <a href="https://www.benzinga.com/etfs">closely watching pharmaceutical ETFs</a> to measure market sentiment and ride out the emerging volatility. 
With President Donald Trump&#8217;s administration rehashing contentious ideas on drug pricing and manufacturing policy, the stakes are increasing — not only for Big Pharma, but for the overall healthcare investment environment.
Amid the trends, pharma-targeted ETFs are being watched under a more risk-averse lens. Each of the funds provides sector exposure, but structural idiosyncrasies — and varying levels of protection from regulation-induced shocks — are gaining heightened relevance.
<h1 class="wp-block-heading">Slicing Up The Pharma ETF Scene</h1>
iShares U.S. Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>)
The ETF offers concentrated exposure to large-cap U.S.-listed pharma companies. Its top holdings are Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), and Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) — companies with strong pipelines and international revenue streams.
Defensive Tilt: IHE&#8217;s emphasis on blue-chip names makes it a relatively defensive play during periods of political unrest.
Policy Sensitivity: But its large weighting in companies with substantial Medicaid and U.S. sales exposure renders it highly sensitive to pharmaceutical pricing reform in the domestic market.
SPDR S&amp;P Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPH#NYSE">XPH</a>)
Unlike IHE, the SPDR S&amp;P Pharmaceuticals ETF uses an equal-weighting style, dispersing exposure across a larger segment of the industry, including mid- and small-cap companies such as Viatris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>).
Diversified Risk: This format caps overconcentration in a single name and increases sensitivity to prospective M&amp;A action.
Higher Volatility: As more importance is assigned to lesser-known participants, XPH can see greater price volatility, particularly as regulatory threats play out.
VanEck Pharmaceutical ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPH#NASDAQ">PPH</a>)
Those in search of global exposure should look at PPH, which includes international powerhouses such as AstraZeneca (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) and Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) on par with U.S. behemoths.
Geopolitical Hedge: International diversification renders PPH less susceptible to U.S.-specific tariff risks or reforms.
Growth Exposure: Novo Nordisk&#8217;s dominance of GLP-1-based obesity treatment provides a high-growth component, although subject to some headwinds due to compounding alternatives in the U.S.
<h1 class="wp-block-heading">Volatility Ahead?</h1>
These ETF dynamics are unfolding against a backdrop of sweeping proposals and heightened industry-government tension. The Trump administration's <a href="https://www.benzinga.com/markets/25/04/44945973/trump-administration-considers-lowering-us-drug-prices-to-international-levels-report">revived push to tether Medicaid drug prices to lower international benchmarks</a> has sent shockwaves through the pharmaceutical sector. Industry analysts estimate the pricing framework could erase as much as $1 trillion in revenue over a decade, according to Bloomberg.
Surprised by the White House&#8217;s latest move, drug industry executives have mounted a concerted lobbying effort, trying to keep the policy from taking hold in Congress. Although some Republican lawmakers, including Kentucky Rep. Brett Guthrie, have reaffirmed their opposition to global reference pricing, the proposal is still a live political threat, Bloomberg reported.
And adding to investor anxiety is Trump&#8217;s latest threat of<a href="https://www.benzinga.com/25/04/44708204/trump-hints-at-major-tariff-on-imported-pharmaceuticals-us-pharma-stocks-tumble-in-wednesday-pre-market"> sector-specific tariffs on drugs</a>. Although the Department of Commerce&#8217;s Section 232 investigation can take months, the threat of new import tariffs — particularly on Indian generics and contract-manufactured products — has already spilled over into related stocks. Insiders within the industry say the administration might move while there is a 90-day moratorium on reciprocal tariff imposition.
Not all of Washington&#8217;s signals are bearish, though. A recently signed executive order is intended to <a href="https://www.benzinga.com/government/regulations/25/05/45215281/trump-orders-fda-to-fast-track-us-drug-production-as-tariff-threat-looms-on-imported-medicines-cites-national-security-concerns">lower FDA approval times for U.S. manufacturing plants</a> — potentially speeding up reshoring and encouraging investment in U.S.-based production. For more exposed domestic manufacturers and smaller company-focused ETFs such as XPH, this may be a long-term tailwind.
<h1 class="wp-block-heading">Proceed, But With Prescription-Strength Caution</h1>
For those looking for exposure to the pharma industry, ETFs are still an important tool — but their variations are more important than ever.
IHE provides stability but is heavily influenced by the success of U.S. policy.
XPH offers balanced exposure and is potentially more sensitive to reforms in domestic manufacturing.
PPH offers a global cushion, especially useful if U.S.-focused risks increase.
In the end, pharma ETFs&#8217; future may depend less on laboratory discoveries than on the political medicine doled out by Washington. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/new-etfs/25/05/45259802/vistashares-launches-qusa-etf-targeting-15-annual-yield-with-quality-us-stocks-options-overlay">VistaShares Launches QUSA ETF, Targeting 15% Annual Yield With Quality U.S. Stocks, Options Overlay</a></li>
</ul>
Photo: Aria Armoko via Shutterstock

Sector ETFs

Trading Ideas

ETFs

iShares Dow Jones US Pharmaceuticals Index Fund

Merrill Lynch Pharmaceutical HOLDRs Trust

VTRS

Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks

AstraZeneca and Daiichi Sankyo's ENHERTU followed by THP showed an improved safety profile vs. standard of care
First Phase III trial to demonstrate benefit of ENHERTU in early breast cancer
Positive high-level results from the DESTINY-Breast11 Phase III trial showed ENHERTU&#xAE; (fam-trastuzumab deruxtecan-nxki)followed by paclitaxel, trastuzumab and pertuzumab (THP) demonstrated a statistically significant and clinically meaningful improvement in pathologic complete response (pCR) rate versus standard of care (dose-dense doxorubicin and cyclophosphamide followed by THP [ddAC-THP]) when used in the neoadjuvant setting (before surgery) in patients with high-risk, locally advanced HER2-positive early-stage breast cancer. Pathologic complete response is defined as no evidence of invasive cancer cells in the removed breast tissue and lymph nodes following treatment.
The secondary endpoint of event-free survival (EFS) was not mature at the time of analysis; however, EFS data showed an early positive trend favoring ENHERTU followed by THP compared to standard of care. The trial will continue to follow EFS.

AstraZeneca And Daiichi Sankyo's ENHERTU Followed By THP Shows Improved Safety Profile Vs. Standard Of Care

Tempus AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>) during the first quarter secured a multi-million dollar deal to build &#8220;the world&#8217;s largest foundation model for oncology.&#8221;
What Happened: During its <a href="https://benzinga.com/general/health-care/25/05/45238450/tempus-ai-q1-earnings-revenue-beat-eps-beat-raised-fy-guidance-shares-surge">first-quarter earnings</a> call on Tuesday, Tempus shed light on its new $200 million, three-year data and modeling license agreement with AstraZeneca PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) and Pathos AI, aimed at developing a foundational model to support diagnostics and drug discovery in oncology.
&#8220;And this is big for a few reasons,&#8221; said Tempus CEO Eric Lefkofsky. <a href="https://www.benzinga.com/news/contracts/25/04/44960263/tempus-ai-stock-is-ripping-higher-wednesday-whats-fueling-the-move">This deal</a> brings the company's total remaining contract value to $1 billion and provides access to more than 300 petabytes of rich multimodal data linked to outcomes. Most importantly, Lefkofsky added, a substantial portion of the computing costs will be covered by AstraZeneca and Pathos AI.
See More: <a href="https://www.benzinga.com/general/health-care/25/05/45245367/novo-nordisks-weight-loss-blockbuster-faces-setback-from-us-compounding-surge-forecast-trimmed">Novo Nordisk&#8217;s Weight Loss Blockbuster Faces Setback From US Compounding Surge, Forecast Trimmed</a>
Lefkofsky says that the model is expected to be completed within 9 to 12 months, following which, each party will get a copy, &#8220;AZ [AstraZeneca] and Pathos to advance their drug discovery efforts and Tempus to advance its diagnostic and data products,&#8221; he says.
Lefkofsky also emphasized that the agreement is non-exclusive, allowing Tempus to license its data and collaborate on model development with other partners in the future. &#8220;We can essentially license data and build models with others, and we hope to do so,&#8221; he said, underscoring the broader strategic value of the deal.
Why It Matters: Tempus shares have been popular among retail investors ever since Former House Speaker Nancy Pelosi <a href="https://www.benzinga.com/trading-ideas/movers/25/01/43131818/whats-going-on-with-tempus-ai-shares-wednesday">disclosed her position</a> in the company, early this year. 
There has also been a big <a href="https://benzinga.com/25/02/43805475/big-bets-on-ai-powered-precision-medicine-major-funds-from-ark-and-jpmorgan-to-blackrock-and-citadel-add-tempus-ai-to-their-portfolio">surge in institutional holdings</a> in recent months, with the likes of JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>), BlackRock Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>), and Cathie Wood&#8217;s Ark Invest all scooping up its shares. 
The company reported $255.76 million in revenue <a href="https://benzinga.com/general/health-care/25/05/45238450/tempus-ai-q1-earnings-revenue-beat-eps-beat-raised-fy-guidance-shares-surge">during the first quarter</a>, up 75.4% YoY, and ahead of consensus estimates at $248.13 million. It posted a loss of $0.24 per share, beating analyst estimates forecasting a loss of $0.27 per share. 
Price Action: Tempus shares were down 3.48% on Tuesday, and it is currently down another 1.72% after hours.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="802" height="214" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07043346/Screenshot-2025-05-07-at-2.03.35-PM.png" alt="" class="wp-image-905084" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07043346/Screenshot-2025-05-07-at-2.03.35-PM.png 802w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07043346/Screenshot-2025-05-07-at-2.03.35-PM-300x80.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07043346/Screenshot-2025-05-07-at-2.03.35-PM-768x205.png 768w" sizes="(max-width: 802px) 100vw, 802px" /></figure>
The stock has a favorable price trend in the short, medium, and long term according to Benzinga&#8217;s Edge Stock Rankings. For more insights, sign up for <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">Benzinga Edge</a>.
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45245680/trump-to-reportedly-lower-china-tariffs-to-60-in-coming-weeks-predicts-investment-strategist-could-be-the-last-big-upside-catalyst-for-a-while">Trump May Lower China Tariffs To 60% In Coming Weeks, Says Piper Sandler Investment Strategist: &#8216;&#8230;Could Be The Last Big Upside Catalyst For A While&#8217;</a></li>
</ul>
Photo courtesy: Piotr Swat / Shutterstock.com

Markets

Tempus AI Strikes $200M Deal With AstraZeneca, Pathos To Build World's Largest Oncology Model

<ul>
<li>Daiichi Sankyo and AstraZeneca's ENHERTU followed by THP showed an improved safety profile versus standard of care</li>
<li>First phase 3 trial to demonstrate benefit of ENHERTU in early breast cancer</li>
<li>Results will be shared with regulatory authorities</li>
</ul>

DSNKY

AstraZeneca And Daiichi Sankyo's ENHERTU Achieves Significant pCR Gains With Improved Safety Profile In Early HER2 Positive Breast Cancer Patients

The European Commission Has Approved Astrazeneca's Calquence (Acalabrutinib) In Combination With Bendamustine And Rituximab For Adult Patients With Previously Untreated Mantle Cell Lymphoma Who Are Not Eligible For Autologous Stem Cell Transplant

On Friday, AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) reported topline data from Phase 3 KALOS and LOGOS trials in patients <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">with uncontrolled asthma</a>.
KALOS and LOGOS trials assessed the efficacy and safety of Breztri Aerosphere&nbsp;(budesonide/glycopyrronium/formoterol fumarate or BGF) compared with two fixed-dose, dual-combination therapies of budesonid (an ICS) and formoterol fumarate (LABA) and&nbsp;Symbicort&nbsp;pressurized metered-dose inhaler (pMDI).
KALOS and LOGOS included approximately 4,400 randomized patients.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44083934/amgen-astrazeneca-partnered-asthma-drug-shows-rapid-and-sustained-effect-in-chronic-rhinosinusitis" rel="noreferrer noopener">Amgen-AstraZeneca Partnered Asthma Drug Shows Rapid And Sustained Effect In Chronic Rhinosinusitis</a>
The <a target="_blank" href="https://www.astrazeneca.com/media-centre/press-releases/2025/breztri-met-primary-endpoints-in-ph3-asthma-trials.html" rel="noreferrer noopener">trials</a> met all primary endpoints, demonstrating a statistically significant and clinically meaningful improvement in lung function compared with dual-combination inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) medicines.
No new safety or tolerability signals were identified for&nbsp;Breztri&nbsp;in KALOS or LOGOS.
Full results from the two Phase 3 trials will be shared with regulatory authorities and presented at an upcoming medical meeting.
Breztri&nbsp;is an inhaled triple-combination therapy approved for chronic obstructive pulmonary disease (COPD) in adults in more than 80 countries worldwide, including the US, EU, China, and Japan.
In addition to the two registrational trials (KALOS and LOGOS),&nbsp;two qualifying trials, LITHOS and VATHOS, also met their primary endpoints. LITHOS and VATHOS included approximately 1,000 randomized patients.
In April, Sanofi SA&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) reported&nbsp;preliminary results from the TIDE-Asthma phase 2 study of amlitelimab and its efficacy in <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44822758/sanofi-asthma-drug-misses-primary-goal-plans-for-pivotal-study" rel="noreferrer noopener">heterogeneous inflammatory asthma</a>.
<ul>
<li>The primary endpoint of the annualized exacerbation rate at week 48 was not met at the highest dose level, leading to nominal significance at the medium and low doses.</li>
<li>Treatment with amlitelimab led to nominally significant and clinically meaningful reductions in asthma exacerbations at the medium dose tested and a numerically greater reduction in exacerbations at the high dose at week 60.</li>
<li>A nominally significant and clinically meaningful improvement in secondary endpoints of lung function and asthma control was evident.</li>
<li>In a patient subgroup, amlitelimab showed nominally significant and clinically meaningful improvements in exacerbations (with a reduction of more than 70%), lung function, and asthma control at week 60.</li>
</ul>
AstraZeneca announced in its&nbsp;first-quarter presentation&nbsp;(PDF) on Tuesday that it had <a target="_blank" href="https://www.astrazeneca.com/content/dam/az/PDF/2025/q1/Q1-2025-results-clinical-trials-appendix.pdf" rel="noreferrer noopener">stopped</a> working on a phase 1 Alzheimer's disease drug and two phase 2 programs for migraine and osteoarthritis pain and painful diabetic neuropathy.
On Tuesday, the European pharma giant reported first-quarter 2025 sales of $13.59 billion, up 7% year over year (+10% at constant currency), slightly missing the&nbsp;consensus of $13.71 billion, driven by double-digit growth in <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/45069668/astrazeneca-q1-sales-and-earnings-rise-warns-china-import-tax-could-be-up-to-8-million-ceo-says-tariff-related-exposure-limited" rel="noreferrer noopener">oncology and biopharmaceuticals</a>.
Price Action: AZN stock is up 1.52% at $71.58&nbsp;at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/05/45165804/cigna-ceo-says-strong-q1-earnings-increased-outlook-reflect-strength-in-growth-platforms" target="_blank" rel="noreferrer noopener">Cigna CEO Says Strong Q1 Earnings, Increased Outlook Reflect Strength In Growth Platforms</a></li>
</ul>
Photo by Piotr Swat Shutterstock

Movers

AstraZeneca's Triple-Combination Therapy Breztri Hits Primary Goals In Two Pivotal Studies For Asthma

Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca's fixed-dose triple-combination therapy BREZTRI AEROSPHERE (budesonide/glycopyrronium/formoterol fumarate or BGF (320/28.8/9.6μg)) met all primary endpoints, demonstrating a statistically significant and clinically meaningful improvement in lung function compared with dual-combination inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) medicines.
KALOS and LOGOS were replicate, randomized, double-blind trials designed to investigate BREZTRIas a potential treatment for asthma.1,2 The trials evaluated the efficacy and safety of BREZTRIversus maintenance treatment with ICS/LABA in adults and adolescents with uncontrolled asthma.

AstraZeneca's Fixed-Dose Triple-Combination Therapy BREZTRI AEROSPHERE Meets Primary Endpoints In KALOS And LOGOS Phase III Trials In Asthma

High-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca's fixed-dose triple-combination therapy Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate or BGF (320/28.8/9.6μg)) met all primary endpoints, demonstrating a statistically significant and clinically meaningful improvement in lung function compared with dual-combination inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) medicines.

AstraZeneca Reported High-level Results From The Phase 3 KALOS and LOGOS Trials, Showing Fixed-dose Triple-combination Therapy Breztri Aerosphere Met All Primary Endpoints In Patients With Uncontrolled Asthma

AstraZeneca's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NYSE">AZN</a>) short percent of float has fallen 41.18% since its last report. The company recently reported that it has 6.33 million shares sold short, which is 0.2% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>AstraZeneca Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745956820_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for AstraZeneca has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing AstraZeneca's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, AstraZeneca's peer group average for short interest as a percentage of float is 3.85%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

What Does the Market Think About AstraZeneca?

AstraZeneca Plc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) on Tuesday reported first-quarter 2025 sales of $13.59 billion, up 7% year over year (+10% at constant currency), slightly missing the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $13.71 billion</a>, driven by double-digit growth in oncology and biopharmaceuticals.
The company&#8217;s adjusted EPADS&nbsp;reached&nbsp;$1.25, beating the consensus of $1.11. The adjusted EPS was $2.09 (1 ADR = 2 Common Shares).
AstraZeneca&#8217;s top business, oncology,&nbsp;<a href="https://www.astrazeneca.com/content/dam/az/PDF/2025/q1/Q1-2025-results-announcement.pdf" target="_blank" rel="noreferrer noopener">increased</a>&nbsp;10% (up 13% on constant currency) to $5.64 billion.
<ul>
<li>Tagrisso sales were up 5% to $1.68 billion (8% at CER), Imfinzi revenues were up 13% (+16%) to $1.26 billion, Calquence sales increased 6% to $762 million, Lynparza sales increased 3% (+8%) to $726 million, and Enhertu revenue was up 29% (39% at CER) to $596 million.</li>
<li>On Tuesday, The Committee for Medicinal Products for Human Use of the European Medicines Agency <a href="https://www.astrazeneca.com/media-centre/press-releases/2025/fixed-duration-calquence-recommended-in-eu-for-cll.html" target="_blank" rel="noreferrer noopener">recommended</a> approving a fixed-duration regimen of Calquence&nbsp;in combination with venetoclax, with or without obinutuzumab, for adult patients with previously untreated chronic lymphocytic leukemia.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/25/04/44851905/trumps-new-order-targets-drug-pricing-transparency-and-medicare-cost-reduction" rel="noreferrer noopener">Trump&#8217;s New Order Targets Drug Pricing Transparency And Medicare Cost Reduction</a>
Cardiovascular, Renal, and Metabolism (CVRM) sales increased 8% (up 12% at CER) to&nbsp;$3.25 billion.
<ul>
<li>Farxiga sales were up 11% (16% at CER) to $2.06 billion.</li>
</ul>
Respiratory &amp; Immunology (R&amp;I) sales increased 11% (13% CER) to $2.08 billion.
<ul>
<li>Symbicort revenues fell 6% (-3% CER) to $723 million, and Fasenra sales increased 17% (+19%) to $418 million.</li>
</ul>
Rare Disease drug sales decreased by 3% to&nbsp;$2.04 billion.
<ul>
<li>Ultomiris sales were up 22% (25% at CER) to $1.05 billion, offset by a 40% decline in Soliris (38% at CER) to $444 million.</li>
</ul>
China: In relation to the illegal drug importation <a href="https://www.wsj.com/health/pharma/astrazeneca-sales-earnings-rise-warns-of-mounting-legal-challenges-in-china-718ddef7">allegations</a>, AstraZeneca received an Appraisal Opinion from the Shenzhen City Customs Office regarding suspected unpaid importation taxes amounting to $1.6 million, referring to the Appraisal Opinion related to Enhertu.
<ul>
<li>A fine of between one and five times (up to $8 million) the amount of unpaid importation taxes may also be levied if AstraZeneca is found liable.</li>
<li>China&#8217;s sales accounted for 13% of quarterly sales, which is up 3% on a reported basis to&nbsp;<a href="https://www.benzinga.com/general/biotech/25/02/43527514/astrazeneca-q4-earnings-revenue-and-eps-beat-on-higher-cancer-and-respiratory-drug-sales-faces-4-5-million-potential-fine-in-china" target="_blank" rel="noreferrer noopener">$1.81 billion (+5% at CER)</a>.</li>
</ul>
AstraZeneca CEO Pascal Soriot said the company is &#8220;firmly committed to investing and growing in the U.S.&#8221; and continues to benefit from a &#8220;broad-based source of revenue and global manufacturing footprint.&#8221; 
AstraZeneca has 11 production sites in the U.S. covering small molecules, biologics as well as cell therapy. It also has two large R&amp;D sites in Gaithersburg MD and Cambridge MA.&#8221;
Guidance:&nbsp;For fiscal year 2025, AstraZeneca forecasts total revenue to increase by a high single-digit percentage and core EPS to increase by a low double-digit percentage.
On Tuesday, AstraZeneca <a target="_blank" href="https://www.astrazeneca.com/media-centre/press-releases/2025/update-on-capitello-280-phase-iii-trial.html" rel="noreferrer noopener">announced</a> the discontinuation of its CAPItello-280 Phase 3 trial of Truqap&nbsp;(capivasertib) in combination with docetaxel and androgen-deprivation therapy (ADT) compared to docetaxel and ADT with placebo in patients with metastatic castration-resistant prostate cancer.
The Independent Data Monitoring Committee reviewed and concluded that the&nbsp;Truqap&nbsp;combination was unlikely to meet the dual primary endpoints of radiographic progression-free survival and overall survival versus the comparator arm upon trial completion.
Price Action:&nbsp;AZN stock is down 0.13% at $69.84 during the premarket session on last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/04/45051380/plaintiff-sues-eli-lilly-johnson-johnson-over-alleged-breast-cancer-risk-linked-to-antipsychotic-medications" target="_blank" rel="noreferrer noopener">Plaintiff Sues Eli Lilly, Johnson &amp; Johnson Over Alleged Breast Cancer Risk Linked To Antipsychotic Medications</a></li>
</ul>
Image: Shutterstock

Earnings

Guidance

AstraZeneca Q1 Earnings Rise, But China Drug Allegations May Lead To $8 Million Penalty

U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Tuesday.
Shares of NXP Semiconductors N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) fell sharply in today's pre-market trading after the company reported first-quarter financial results and issued second-quarter EPS guidance with its <a href="https://in.benzinga.com/news/management/25/04/45053723/nxp-semiconductors-reports-q1-earnings-very-uncertain-operating-environment-tied-to-tariffs-ceo-transition-shares-fall">midpoint below estimates</a>.
NXP reported first-quarter revenue of $2.84 billion, in line with analyst estimates, according to Benzinga Pro. The company reported first-quarter adjusted earnings of $2.64 per share, beating analyst estimates of $2.58 per share.
NXP expects second-quarter revenue of $2.8 billion to $3 billion versus estimates of $2.87 billion. The company sees second-quarter adjusted earnings in the range of $2.46 to $2.86 per share versus estimates of $2.65 per share. The company announced CEO Kurt Sievers will retire at the end of 2025.
NXP Semiconductors shares dipped 7.7% to $181.18 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Ultra Clean Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCTT#NASDAQ">UCTT</a>) fell 10.3% to $20.00 in pre-market trading after the company reported worse-than-expected first-quarter financial result and issued second-quarter guidance below estimates.</li>
<li>Hope Bancorp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOPE#NASDAQ">HOPE</a>) declined 9.5% to $9.02 in pre-market trading.</li>
<li>Brinker International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAT#NYSE">EAT</a>) dipped 8.6% to $146.90 in pre-market trading following third-quarter results.</li>
<li>Spotify Technology S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) fell 8.5% to $547.00 in pre-market trading after the company reported worse-than-expected quarterly earnings.</li>
<li>Syndax Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) fell 7.5% to $12.42 in pre-market trading. Syndax Pharmaceuticals will report its first quarter financial results and provide a business update on Monday, May 5.</li>
<li>Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) fell 7% to $568.00 in pre-market trading following weak quarterly earnings.</li>
<li>Sanmina Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANM#NASDAQ">SANM</a>) fell 5.8% to $76.00 in today's pre-market trading. Sanmina posted upbeat results for its second quarter, but issued weak forecast for the third quarter. The company said it sees third-quarter adjusted earnings of $1.35 to $1.45 per share, versus market estimates of $1.53 per share. It also expects sales of $1.925 billion to $2.025 billion for the current quarter, versus market projections of $2.06 billion.</li>
<li>XPeng Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) fell 4.7% to $18.99 in pre-market trading.</li>
<li>BP p.l.c. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>) declined 4.3% to $27.87 in pre-market trading following first-quarter earnings.</li>
<li>AstraZeneca PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) fell 2.8% to $67.96 in pre-market trading following quarterly results.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45060164/general-motors-coca-cola-and-3-stocks-to-watch-heading-into-tuesday">General Motors, Coca-Cola And 3 Stocks To Watch Heading Into Tuesday</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

HOPE

NXPI

REGN

SANM

SNDX

SPOT

UCTT

XPEV

NXP Semiconductors, Brinker International, Ultra Clean, Sanmina And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

U.S. stock futures rose Tuesday morning as investors looked ahead to upcoming earnings reports and awaited greater market clarity throughout the week.
Things haven&#8217;t moved all that much on the trade and tariffs front, with Treasury Secretary Scott Bessent merely stating on Monday that <a href="https://www.benzinga.com/25/04/45038824/treasury-secretary-scott-bessent-says-its-up-to-china-to-de-escalate-trade-tensions-india-to-be-the-first-trade-deal-to-be-signed">it was up to China</a> to &#8220;de-escalate&#8221; trade tensions. Bessent also hinted at a potential trade deal with India, saying that &#8220;it would be one of the first deals we would sign,&#8221; which investors will be watching closely.
This is set to be a packed earnings week for Wall Street, with four of the &#8220;Mag 7&#8243;— Microsoft&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>),&nbsp;Meta&nbsp;Platforms&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>),&nbsp;Apple&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>),&nbsp;and Amazon&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), set to release their quarterly results over the next couple of days.
On Tuesday, investors will be closely watching the results of several heavy-hitters, such as Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>), Coca-Cola Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>), Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>), AstraZeneca PLC (NASDAQ:&nbsp;AZN), and Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>).
U.S. 10-Year Treasuries are at 4.23%, while the 2-Year Treasuries are at 3.70%. The CME Group's FedWatch&nbsp;<a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a>&nbsp;shows the markets pricing a 91.1% likelihood of interest rates remaining unchanged during the FOMC meeting, the first week of May, marking a decline from Friday last week, at 95.3%, and Monday at 93.1%
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td class="has-text-align-center" data-align="center">Futures</td>
<td class="has-text-align-center" data-align="center">Change (+/-)</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Dow Jones</td>
<td class="has-text-align-center" data-align="center">0.28%</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">S&amp;P 500</td>
<td class="has-text-align-center" data-align="center">0.20%</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Nasdaq 100</td>
<td class="has-text-align-center" data-align="center">0.21%</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Russell 2000</td>
<td class="has-text-align-center" data-align="center">0.19%</td>
</tr>
</tbody>
</table>
</figure>
The&nbsp;SPDR S&amp;P 500 Trust ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was up 0.04% on Monday, while the Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which tracks the Nasdaq-100 Index was down 0.03%, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;138z7gr&#x2A;_gcl_au&#x2A;MjA5Njc0MjY1My4xNzQwODM2NTUw&#x2A;_ga&#x2A;R1MxLjEuMTc0NDY0ODA3Mi4yLjAuMTc0NDY0ODA3NS4wLjAuMA..&#x2A;_ga_V7ZK73W7N0&#x2A;MTc0NTgyOTMzMy4xLjEuMTc0NTgyOTYyMy4wLjAuMA..">Benzinga Pro</a> data. 
Cues From Last Session:
Almost all S&amp;P 500 sectors closed in the green on Monday, barring consumer staples and technology. While the index was up just 0.06%, it marked its fifth-straight winning day. There was no economic data released during the day, just a few earnings releases, which were mixed.
Waste Management Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>), Domino's Pizza Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>), and NXP Semiconductors N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) were few of the companies that reported Monday, with most of them being a mixed bag, with hits and misses across consensus estimates.
See Also: <a href="https://www.benzinga.com/25/04/45057906/palantirs-defense-moat-ex-employee-reveals-how-pltr-could-dominate-ai-defenseamid-pricing-puzzles-and-competitive-pressures" target="_blank" rel="noreferrer noopener">Fortress Palantir: Former Insider Explains How PLTR Could Conquer The AI-Defense Battlefield Despite Pricing Puzzles And Competition</a>
As of Monday, the Nasdaq 100 is down 12.6% from its high of 22,222.61 points, the S&amp;P 500 is down 10% from 6147.43 points, and the Dow Jones Industrial Average is down 10.75% from 45,073.63 points.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td class="has-text-align-center" data-align="center">Index</td>
<td class="has-text-align-center" data-align="center">Performance (+/-)</td>
<td class="has-text-align-center" data-align="center">Value</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Nasdaq Composite</td>
<td class="has-text-align-center" data-align="center">-0.09%</td>
<td class="has-text-align-center" data-align="center">17,366.13</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">S&amp;P 500</td>
<td class="has-text-align-center" data-align="center">0.06%</td>
<td class="has-text-align-center" data-align="center">5,528.75</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Dow Jones</td>
<td class="has-text-align-center" data-align="center">0.28%</td>
<td class="has-text-align-center" data-align="center">40,227.59</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Russell 2000</td>
<td class="has-text-align-center" data-align="center">0.41%</td>
<td class="has-text-align-center" data-align="center">1,965.55</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
According to analysts at Charles Schwab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>), the <a href="https://www.schwab.com/learn/story/weekly-traders-outlook">outlook for the week</a> is being described as &#8220;Volatile,&#8221; given the several mega-cap earnings that are scheduled to be released this week, alongside volatility-inducing economic data, such as the Monthly Jobs Report, Jobless Claims, and more.
Trader and mentor at UIFCA, Eric Daniel, has posted on X that the markets are approaching the perfect volatility storm, in part due to the reasons stated above, alongside the Federal Reserve FOMC meeting on the 6th and 7th of May. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Market approaching the perfect volatility storm: Fed meeting Big tech earnings Jobs report Friday Pre-market action suggests caution. My approach: Reduced position sizes, defined risk strategies, patience for premium opportunities. Discipline &gt; Prediction this week.
&mdash; Eric Daniel (@EricDaniel_NYC) <a href="https://twitter.com/EricDaniel_NYC/status/1916692599714304068?ref_src=twsrc%5Etfw">April 28, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Upcoming Economic Data:
Here&#8217;s what investors will be monitoring on Tuesday,
<ul>
<li>The Advanced U.S. trade balance in goods, Advanced retail inventories, and the Advanced wholesale inventories for March will be out by 8:30 AM ET. </li>
<li>The S&amp;P Case-Shiller home price index (20 cities) for February will be out by 9 AM ET. </li>
<li>The Consumer Confidence Report for April and the Job Openings Report for March will be out by 10 AM ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) shares are up 0.41% in pre-market trade, with the company set to release its earnings after markets close on Tuesday. Analyst consensus estimates stand at $9.5 billion in revenue, and $2.68 per share earnings. </li>
<li>Coca-Cola Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>) is down 0.06% in pre-market trade, as investors wait for the company&#8217;s first quarter results, scheduled to be released before the opening bell. Analysts expect the company to post $0.72 per share in earnings, from $11.2 billion in revenue. </li>
<li>AstraZeneca PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NYSE">AZN</a>) is down 2.57% in pre-market trade. The company just released its earnings, with a miss on top-line estimates, but a beat at the bottom. </li>
<li>Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) is up 0.13% in pre-market trade, with the company set to announce its quarter results before markets open. Analysts expect $0.68 per share in earnings, from $14.1 billion in revenue. </li>
<li>Honeywell International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>) is scheduled to release its quarterly results before markets open, with analysts expecting $2.21 earnings, on $9.6 billion in revenue. The stock is up 0.63% in pre-market trade.</li>
</ul>
Commodities, Gold And Global Equity Markets:
Crude oil futures continue to decline, down 1.10% during the early New York session, trading at $61.37 per barrel. Gold Spot U.S. Dollar is down 0.66%, trading at $3,313 per ounce, down from record high levels of $3.400 per ounce this time last week.
The U.S. Dollar Index (DXY) is up 0.26%, trading at 99.26 against a basket of other currencies.
Asian markets are up on Tuesday, with the Nikkei, Kospi, and the Nifty 50, all in the green, barring the Chinese benchmarks that continue to decline. Australia&#8217;s ASX 200 is up, while New Zealand&#8217;s NZX 50 is down during the day.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/media/25/04/45058018/trumps-145-china-tariffs-spark-seller-backlash-as-amazon-prime-day-2025-faces-pullouts-and-discount-cuts-report" target="_blank" rel="noreferrer noopener">Trump's 145% China Tariffs Spark Seller Backlash As Amazon Prime Day 2025 Faces Pullouts And Discount Cuts: Report</a></li>
</ul>
Photo courtesy: Frontpage / Shutterstock.com

Analyst Color

Equities

Economics

AAPL

ABBV

AMZN

MSFT

SCHW

WELL

US Stock Futures Edge Higher Tuesday: Expert Warns Of 'Perfect Volatility Storm' With Major Earnings And Economic Data Due This Week

ACGL

AEYE

AMSF

APAM

ARCB

ARCC

ASTE

ASTL

ATRC

BBIO

BBVA

BGFV

BKNG

BRSP

CECO

CHCT

CLVT

CSGP

CVLT

DHIL

ENSG

ENVA

ESRT

ETWO

EXLS

FELE

FFIC

FIBK

FICO

FOUR

FRSH

FRST

FSLR

FYBR

HLMN

HOUS

HRZN

HSBC

HURN

ILPT

INCY

INTZ

JAKK

JBGS

JBLU

KNSA

LFUS

LGIH

Laboratory Corporation Of America Holdings

LOGI

LXFR

Earnings Scheduled For April 29, 2025

Guidance
AstraZeneca reiterates its Total Revenue and Core EPS guidance5 for FY 2025 at CER, based on the average foreign exchange rates through 2024.
Total Revenue is expected to increase by a high single-digit percentage
Core EPS is expected to increase by a low double-digit percentage
– The Core Tax rate is expected to be between 18-22%

AstraZeneca Reaffirms 2025 Guidance: Revenue Growth In High Single-Digit, Core EPS Growth In Low Double-Digit Core EPS Growth, And 18–22% Core Tax Rate

AstraZeneca (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) reported quarterly earnings of $1.25 per share which beat the analyst consensus estimate of $1.11 by 12.16 percent. This is a 20.87 percent increase over earnings of $1.03 per share from the same period last year. The company reported quarterly sales of $13.59 billion which missed the analyst consensus estimate of $13.71 billion by 0.89 percent. This is a 7.17 percent increase over sales of $12.68 billion the same period last year.

Earnings Beats

Earnings Misses

AstraZeneca Q1 Adj. EPADS $1.25 Beats $1.11 Estimate, Sales $13.59B Miss $13.71B Estimate

PBYI

Puma Biotechnology Presents Clinical Data Of Phase I Trial Of trastuzumab deruxtecan In Combination With Neratinib In Solid Tumors With HER2 Alterations At AACR 2025

SOPH

Sophia Genetics Expands Collaboration With AstraZeneca To Accelerate The Deployment Of MSK-ACCESS Powered With SOPHiA DDM Globally

These eight mid-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Ascentage Pharma Group Internat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPG#NASDAQ">AAPG</a>) stock jumped 38.35%. The company plans to present data from two clinical studies at the 2025 ASCO Annual Meeting, including an oral presentation for its key <a href="https://www.benzinga.com//node/44968495" target="_blank" rel="noreferrer noopener">assets Lisaftoclax and Alrizomadlin</a>.</li>
<li>Ardagh Metal Packaging (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMBP#NYSE">AMBP</a>) shares escalated 38.66% after the company reported a year-over-year increase in first-quarter adjusted EPS results and better-than-expected revenue results. Additionally, the company raised its FY25 <a href="https://www.benzinga.com//node/44975010" target="_blank" rel="noreferrer noopener">adjusted EBITDA guidance</a>.</li>
<li>Bitdeer Technologies Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTDR#NASDAQ">BTDR</a>) stock gained 38.19% last week. Shares of crypto-related companies have gained amid a rise in the price of Bitcoin. The cryptocurrency continues to face volatility but has decoupled from risk assets this week and has outperformed Gold.</li>
<li>Pegasystems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGA#NASDAQ">PEGA</a>) shares upped 32.85% after reporting better-than-expected <a href="https://www.benzinga.com//node/44936292" target="_blank" rel="noreferrer noopener">first-quarter financial results</a>. Several analysts raised the <a href="https://www.benzinga.com/quote/pega/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast for the stock.</a></li>
<li>Impinj, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PI#NASDAQ">PI</a>) shares increased 31.58% after the company reported better-than-expected financial results and issued <a href="https://www.benzinga.com//node/44964703" target="_blank" rel="noreferrer noopener">second-quarter guidance above estimates</a>. Several analysts revised the <a href="https://www.benzinga.com/quote/pi/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast for the stock.</a></li>
<li>Lufax Holding Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LU#NYSE">LU</a>) stock grew 30.72%, probably amid overall market strength due to March&#8217;s strong durable goods orders economic data and President Trump&#8217;s announcement that he met with China earlier today.</li>
<li>Tempus AI Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>) shares rocketed 30.09% after the company announced a multi-year collaboration with AstraZeneca PLC <a href="https://www.benzinga.com//node/44960263" target="_blank" rel="noreferrer noopener">(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) and Pathos AI</a>.</li>
<li>Kymera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>) stock was up 28.00%. The company initiated dosing in the BroADen phase 1B clinical trial evaluating KT-621, a potent degrader of STAT6, in patients <a href="https://www.benzinga.com//node/44918188" target="_blank" rel="noreferrer noopener">with moderate to severe atopic dermatitis</a>.</li>
</ol>
Photo by Piotr Swat via Shutterstock

Mid Cap

AAPG

AMBP

BTDR

KYMR

PEGA

Bitdeer Tech And Tempus AI Are Among Top 18 Mid-Cap Gainers Last Week (Apr 21-Apr 25): Are The Others In Your Portfolio?

Tempus AI Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>) shares are surging Wednesday after the company announced a multi-year collaboration with AstraZeneca PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) <a href="https://www.benzinga.com/pressreleases/25/04/b44946320/tempus-signs-expanded-strategic-agreements-with-astrazeneca-and-pathos-to-develop-the-largest-mult">and Pathos AI</a>.
What To Know: Tempus AI announced a multi-year, strategic collaboration with AstraZeneca and Pathos to build a multimodal foundation model in oncology. 
The model, which will be built using Tempus&#8217; de-identified oncology data, is expected to be used for the collection of biological and clinical insights, the discovery of novel drug targets and the development of therapeutics for the oncology community as a whole.
The agreement with AstraZeneca expands on the strategic partnership between the two companies. Tempus said the collaboration includes&nbsp;$200 million&nbsp;in data licensing and model development fees. 
&#8220;Generative AI and the emergence of large multimodal models is the final catalyst needed to usher in precision medicine in oncology at scale,&#8221; said Eric Lefkofsky, founder and CEO of Tempus AI.
&#8220;Tempus has spent the last decade investing billions of dollars into collecting the necessary data needed for a foundation model of this kind to take shape. We look forward to working with AstraZeneca and Pathos to apply AI-enabled solutions to advance therapies in an effort to help patients live longer and healthier lives.&#8221;
Tempus AI shares have seen a rise in popularity among retail investors this year ever since former House Speaker&nbsp;Nancy Pelosi&nbsp;<a href="https://www.benzinga.com/trading-ideas/movers/25/01/43131818/whats-going-on-with-tempus-ai-shares-wednesday">disclosed</a> a position in the company. A regulatory filling from January showed that Pelosi purchased 50 call options in Tempus AI on Jan. 14. The calls have a strike price of $20 and don't expire until Jan. 16, 2026.
See Also: <a href="https://www.benzinga.com/news/global/25/04/44858847/nancy-pelosi-called-us-china-trade-a-job-loser-old-remarks-reemerge-amid-trump-tariff-push">Nancy Pelosi Called US-China Trade &#8216;A Job Loser:&#8217; Old Remarks Reemerge Amid Trump Tariff Push</a>
<h3 class="wp-block-heading">How To Buy TEM Stock</h3>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Tempus AI's case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
TEM Price Action: <a href="http://benzinga.com/quote/tem">Tempus AI shares</a> were up 16.5% at $50.37 at the time of publication Wednesday. The AI stock is up approximately 46% year-to-date, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: <a href="https://www.shutterstock.com/g/Piotr+Swat">Piotr Swat</a>/Shutterstock.

Contracts

Tempus AI Stock Is Ripping Higher Wednesday: What's Fueling The Move?

Press Releases

STAAR Surgical Announces Changes to Board of Directors

SOPHiA GENETICS Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACR

Puma Biotechnology Presents Clinical Data on Neratinib at the AACR Annual Meeting 2025

AstraZeneca's Q1 2025 Financial Results

EsoBiotec to Present Preclinical Proof-of-Concept Data for Its Off-the-Shelf ENaBL In Vivo Cell Therapy Platform at the 28th Annual Meeting of the American Society of Gene and Cell Therapy

Small Cap

Opinion

New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty

BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma

ENHERTU® Followed by THP Before Surgery Showed Statistically Significant and Clinically Meaningful Improvement in Pathologic Complete Response in Patients With High-Risk HER2 Positive Early-Stage Breast Cancer in DESTINY-Breast11 Phase 3 Trial

ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11

IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial

BAYRY

BCTX

CRVL

MDRX

ONCY

QSII

STAA

STRO

TSX:BCT

TSX:ONC

TYO:4568

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Comments

AstraZeneca

空売り

AstraZeneca (NASDAQ:AZN) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル